title: Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs--Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
authors.affiliation: Department of Urology, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
authors.forename: K A
authors.initials: KA
authors.lastname: Hanash
authors.forename: J W
authors.initials: JW
authors.lastname: Aquilina
authors.forename: D M
authors.initials: DM
authors.lastname: Barrett
authors.forename: M L
authors.initials: ML
authors.lastname: Blute
authors.forename: A T
authors.initials: AT
authors.lastname: Cockett
authors.forename: F A
authors.initials: FA
authors.lastname: Corica
authors.forename: G G
authors.initials: GG
authors.lastname: Hillman
authors.forename: B
authors.initials: B
authors.lastname: Zbar
authors.forename: Z
authors.initials: Z
authors.lastname: Zhuang
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000517:prevention & control*; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D006292:Health Priorities; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000517:prevention & control*; D018579:Patient Selection; D012107:Research Design
chemical_list: D014408:Biomarkers, Tumor; D016898:Interferon-alpha; D007376:Interleukin-2